The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Establishment of the first international large-scale, genomic screening platform to identify patients with rare oncogene drivers in non-small cell lung cancer (NSCLC) in East Asia.
 
Shingo Matsumoto
Honoraria - AstraZeneca; Chugai Pharma; MSD (Inst); Novartis; Pfizer
Research Funding - Chugai Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst)
 
Caicun Zhou
Honoraria - Boehringer Ingelheim; Hengrui Therapeutics; Innovent Biologics; Lilly; MSD; QiLu Pharmaceutical; Roche
Consulting or Advisory Role - Amoy Diagnostics; Hengrui Therapeutics; Innovent Biologics; QiLu Pharmaceutical
 
Chih-Hsi Kuo
Honoraria - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst)
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Merck (Inst); Novartis (Inst); Takeda (Inst)
 
Kiyotaka Yoh
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Kirin Pharmaceuticals; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Chugai Pharma
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck KGaA; Merck Sharp & Dohme; Nippon Kayaku; Nitto Denko; Novartis; Ono Pharmaceutical; Pfizer; Roche; Shionogi; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Chugai Pharma; Lilly; Merck Serono; MSD; Nitto Denko; Pfizer
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb; Chugai Pharma (Inst); Kyorin; Kyowa Hakko Kirin; Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis; Ono Pharmaceutical (Inst); Pfizer (Inst); Regeneron; Taiho Pharmaceutical (Inst)
 
Kazumi Nishino
Honoraria - AstraZeneca Japan; Chugai Pharma; Lilly; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Roche
Research Funding - Nippon Boehringer Ingelheim
 
Naoki Furuya
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim
 
Shucai Zhang
No Relationships to Disclose
 
Dongmei Lin
No Relationships to Disclose
 
Yuchen Han
No Relationships to Disclose
 
Chin-Chou Wang
No Relationships to Disclose
 
Takaya Ikeda
No Relationships to Disclose
 
Yoshitaka Zenke
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD Oncology; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Koichi Goto
Honoraria - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Guardant Health; IQvia; Janssen; Kyowa Hakko Kirin; Life Technologies; Lilly; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Otsuka
Research Funding - Amgen; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Ignyta; Janssen; Kyowa Hakko Kirin; Life Technologies; Lilly; Loxo; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Riken Genesis; Sumitomo Dainippon; Sysmex; Taiho Pharmaceutical; Takeda; Xcoo